

COMPUGEN LTD  
Form 6-K  
August 01, 2018

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2018

Commission File Number 000-30902

COMPUGEN LTD.  
(Translation of registrant's name into English)

26 Harokmim Street  
Holon 5885849, Israel  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F                      Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

Compugen Ltd.

On August 1, 2018, Compugen Ltd. (the "Company") issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 6-K.

#### Second Quarter 2018 Financial Results

The unaudited interim consolidated financial statements of Compugen Ltd. (the "Company") and its subsidiary as of June 30, 2018 and December 31, 2017 and for the six months ended June 30, 2018 and 2017 are filed as Exhibit 99.2 to this Form 6-K and incorporated by reference herein. The Operating and Financial Review and Prospects of the Company as of and for the six months ended June 30, 2018 and June 30, 2017 are filed as Exhibit 99.3 to this Form 6-K and incorporated by reference herein.

The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statement on Form F-3, File No. 333-213007.

#### Exhibits

##### Exhibit

<u>Number</u>	<u>Description of Exhibit</u>
---------------	-------------------------------

<u>10.1*</u>	<u>Amendment No. 1, dated May 9, 2018, to the License Agreement entered into as of March 30, 2018 by and between Compugen Ltd. and Medimmune, Limited.</u>
--------------	--

<u>99.1</u>	<u>Press Release dated August 1, 2018 – " Compugen Reports Second Quarter 2018 Results"</u>
-------------	---

<u>99.2</u>	<u>Unaudited interim consolidated financial statements as of June 30, 2018 and December 31, 2017 and for the six months ended June 30, 2018 and 2017.</u>
-------------	---

<u>99.3</u>	<u>Operating and Financial Review and Prospects as of and for the six months ended June 30, 2018 and June 30, 2017.</u>
-------------	---

101	The following financial information from Compugen Ltd.'s Report on Form 6-K, formatted in XBRL (eXtensible Business Reporting Language): (i) consolidated balance sheets at June 30, 2018 and December 31, 2017; (ii) consolidated statements of comprehensive loss for the six months ended June 30, 2018 and 2017; (iii) consolidated statements of changes in shareholders' equity for the six months ended June 30, 2018 and the year ended December 31, 2017; (iv) consolidated statements of cash flows for the six months ended June 30, 2018 and 2017; and (v) notes to the consolidated financial statements.
-----	--

---

\* Confidential treatment with respect to certain portions of this exhibit has been requested from the Securities and Exchange Commission. Omitted portions have been filed separately with the Securities and Exchange Commission.

---

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMPUGEN LTD.

Date: August 1, 2018 By: /s/ Donna Gershowitz  
Donna Gershowitz  
General Counsel

---